{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.500","upperLimit":"24.0","value":"2.00"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"5.97","value":"2.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1/Day 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.567","upperLimit":"2.00","value":"1.03"},{"comment":"Based on pre-specified criteria, statistical analysis was not performed if fewer than 3 participants have reportable parameter values.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 2/Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg starting on Day 2 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). Decitabine was given at a dose of 20 mg/m\\^2 as an intravenous (IV) infusion over 1 hour on Days 1-5 of the 28-day cycles.","id":"OG000","title":"Phase 1B: Glasdegib 100 mg + Decitabine"},{"description":"Participants received oral doses of glasdegib tablets 200 mg starting on Day 2 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). Decitabine was given at a dose of 20 mg/m\\^2 as an IV infusion over 1 hour on Days 1-5 of the 28-day cycles.In March 2013, all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 1/Day 24 and Cycle 5/Day 1, respectively.","id":"OG001","title":"Phase 1B: Glasdegib 200 mg + Decitabine"}],"paramType":"MEDIAN","populationDescription":"Dose compliant group:Participants who had at least 4 days of uninterrupted dosing for a multiple dose PK assessment were considered to be at steady state,part of the \"dose compliant\" group.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10; pre-dose, 0.5, 1, 2, 6 and 24 hours post-dose on Cycle 2/Day 1","title":"Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1","type":"SECONDARY","unitOfMeasure":"Hours"}